In:
Clinical and Experimental Pharmacology and Physiology, Wiley, Vol. 45, No. 12 ( 2018-12), p. 1325-1327
Abstract:
Recombinant human endostatin (rh ES ) can inhibit multiple myeloma, while its clinical efficacy in treating relapsed refractory multiple myeloma ( RRMM ) has not been assessed. One hundred and eleven RRMM patients were treated with four different regimens: combination of VD (velcade+dexamethasone) and rh ES (n = 25), Thalidomide (Tha) and VD ( VTD , n = 22) combination, rh ES and conventional chemotherapy combination (n = 32), and combination of conventional chemotherapy and Tha (n = 32). Significant differences were found in progression‐free survival ( PFS ) between rh ES combination groups and conventional chemotherapy combination groups. No statistical difference was found in overall response rate, overall survival or incidences of adverse effects. The combination of rh ES with VD or conventional chemotherapy is active in patients with RRMM and prolongs the PFS to improve the quality of life.
Type of Medium:
Online Resource
ISSN:
0305-1870
,
1440-1681
DOI:
10.1111/cep.2018.45.issue-12
DOI:
10.1111/1440-1681.13016
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2020033-X
SSG:
15,3
Permalink